Introduction: Another antihypertensive drug has been launched, its name is called shakuba tridansartan, which is said to be especially suitable for The Chinese people to protect the heart and kidneys from damage from the drug ingredients when they are strongly controlled by pressure. Future medicines all seem to have one characteristic.
In the process of exerting drug effect and controlling pressure, it is also necessary to take into account the safety of other organs, which can greatly improve the cure rate and quality of life of patients, and it is also the idea that every scientist hopes to benefit mankind.
Sacubatri valsartan is currently one of the latest antihypertensive drugs, it is an angiotensin receptor cerebral phenolphtase inhibitor, this drug is synthesized by two agents, one is the traditional antihypertensive drug angiotensin receptor blocker, which is what we call valsartan, the other is a cerebral linorpeptase inhibitor, which is what we usually call sacobatra.
By combining the functions of the two agents, they will play an important role in each of them, and with the approval of the US Food and Drug Administration, the drug is currently used in first-line treatment options and is likely to be an important basis for treating heart failure.
This drug has a good effect and is used in a variety of diseases, let's take a look at how much it plays a role in different diseases.
(1) Sakuba tri valsartan will be applied in acute aberration banded heart failure
Let's first talk about what role sakubaqu and valsartan play in the treatment of heart failure, first of all, sakubaqu, in the recent 20 years of research, scientists found that sakubaqu blocked the cerebral lining peptidase, promote endogenous sodium urea peptide degradation, correspondingly will make naturate peptide play its beneficial role.
Valsartan can improve our human body's myocardial reconstruction to alleviate the possible development of heart failure in the direction of sound sources, reduce patient mortality and improve prognosis, and have good results.
After 8 weeks of treatment with this drug, patients can feel that the severity of heart failure has decreased more quickly and significantly, and the level of amino terminal brain natriuretic peptide precursors has decreased to 29%, and from this data, we can see that the efficacy of this drug is still quite good.
(2) Sakuba tridranessartan will be applied in myocardial infarction
Myocardial infarction has the characteristics of "four highs", one is a high prevalence rate, the second is a high rate of spontaneous birth, the third is a high recurrence rate, the fourth is a high mortality rate, and then the traditional drugs that treat myocardial infarction may not have a great effect, but traditional drugs are not useless, and the relief effect they play is also very important. Sakubatri valsartan has a clear advantage in the treatment of this aspect, because the drug will inhibit the production of the pro-inflammatory factor aldosterone, the matrix metalloproteinase 9 activity in the human body will be reduced, and the nauuripeptide activity will be enhanced.
(3) Sakubal valsartan will be applied in heart failure
Sakubatraxsartan is able to improve the symptoms of patients with heart failure, and has a very good effect on the percutaneous coronary intervention in patients with acute st-segment elevation anterior myocardial infarction and heart failure, and the incidence of adverse reactions is lower than that of patients using enalapril after 6 months of sakuba tridansartan. Although the drug has a good effect, the drug's compliance and long-term efficacy in treating patients with heart failure need to be further confirmed by doctors.
(4) Sakuba tridinasartan will be applied to hypertension
How to reduce hypertension, has been a problem that most doctors and patients are very concerned about, some drugs are good, but the side effects are large, some drug side effects are not large, but the efficacy is generally how to choose, which is a difficult point of traditional drugs, but after the introduction of sakuba triacchartan, it is very good for anti-stress treatment of hypertension patients.
Sakuba tri valsartan will act in the cell signaling pathway, with the pathophysiology of the occurrence mechanism, to hypertensive patients with a new pharmacological target, this drug can dilate systemic blood vessels, diuretic and natriuretic, antihypertensive effect is strong, and suitable for a wide range of patients, such as senile hypertension, nocturnal hypertension, drug-resistant hypertension, central arterial hypertension, Asian population hypertension have a better effect.
Any drug has corresponding side effects, the key is whether its side effects are large or small, the frequency caused is more or less, in addition to how the patient's personal constitution is, more sensitive to a certain drug, the number of adverse reactions after use is larger, then we will not recommend him to use this drug, as a new star representative in the anti-blood pressure circle, how safe is sacuba tridacvosartan, let's take a look.
(1) It may cause angioedema
Patients with sakubatro valsartan treatment process will occur angioedema, which is confirmed by blind rulings, so in the process of using the drug, to observe whether there is angioedema, especially for patients with a certain sensitivity to this drug, the probability of angioedema is greater than that of the general population, if necessary, you can stop taking the drug, choose other drugs for treatment, reduce the risk of angioedema.
(2) May cause hypotension
Shakuba Tri valsartan has a strong antihypertensive ability, but it is possible that it cannot stop the car and fall into a state of hypotension. Many patients have hypotension after treatment with sakubatri valsartan, and analysis has shown that patients with low baseline systolic blood pressure will have a significantly increased mortality and cardiovascular incidence, which means that there is a certain risk of hypotension.
(3) May cause renal insufficiency
In some patients with renal insufficiency, the use of sakuba trivasartan can cause corresponding adverse reactions. For mild to moderate renal insufficiency, patients do not need to adjust the dose when using sacobatrical valsartan, while patients with severe renal insufficiency, in the absence of corresponding research data, the initial dose of sakuba triacchartan is recommended to use 50mgbid, and it should be noted that sakubatroxsartan is not used in combination with arb, otherwise it will have serious consequences, and attention should be paid to the observation of renal function.
(4) May cause hyperkalemia
The gastric action of sakubatri valsartan in the renin-angiotensin-aldosterone system may increase the risk of hyperkalemia, so after the occurrence of adverse reactions, the drug can be discontinued to prevent further increase and deepening of adverse reactions.
After clarifying the efficacy of this drug and the possible side effects, this requires us to use the drug in accordance with certain scientific norms while using the cobatrozatan, and we have summarized several good tips for everyone.
I. Pay attention to regular dosage
The usual dosage of sakubatri valsartan is 200 mg once a day, for patients with refractory hypertension, the dosage can be appropriately increased, but not too much, generally 300 to 400 mg / day.
II. Can be combined with other antihypertensive drugs
The prerequisite for combining with other antihypertensive drugs is that the blood pressure will be up to standard, but the dose increase is limited, when using sakubatri valsartan, you can not increase its own dose, but use a combination with other types of antihypertensive drugs, another point to note is that it can not be used in combination with ras inhibitors.
III. Disabled population
Sakubatri valsartan is not suitable for some patients, such as patients with severe renal impairment, renal artery stenosis and moderate liver function impairment, these two types of people should be used with caution or banned.
IV. Propharmaceuticals should pay attention to monitoring
The combination of sakuba triacchartan and other cardiovascular drugs will interact with each other, at this time we should regularly monitor blood potassium, blood pressure, kidney function, liver function, etc., to avoid abnormalities.
Conclusion: Sakubatricsartan is a newly launched antihypertensive drug, for the heart and kidney disease has a good treatment and control effect, very suitable for China's large cardinal disease patients to use, in the use of this drug, we should be aware of its possible side effects, and in accordance with the corresponding instructions to use the drug, do not arbitrarily use drugs or in combination with other drugs, you can go to the hospital to do relevant examinations and then see if you can choose this drug.
literature: Chen Qiying,Li Yimin,Chen Wenfa. Analysis of adverse reactions of sakubatri valsartan based on faers[j].Chinese Journal of Hospital Pharmacy,2021,41(03):264-268. Guo Ning,Huang Sulan,Ge Liangqing. Application of sakuba tridansal sartan in cardiovascular diseases[j].Chinese Journal of Hypertension,2020,28(09):876-879. Liu Tao,Xu Junbo,Wu Jing. New advances in the treatment of heart failure by sakubatri valsartan[j].Advances in Cardiology,2018,39(03):483-486. [4] Bai Yujia,Xu Dingli. Safety review of sakuba tridevacesartan[j].Chinese Journal of Recycling,2018,33(02):206-208.